Riffyn Blog

In a recent interview with Peta Crunch, Riffyn Founder and CEO Timothy Gardner shares what Riffyn has accomplished and what its future will hold. Tim provides six examples of how Riffyn has helped customers achieve significant breakthroughs and the exciting direction the company is moving.

The barrier to unlocking the full potential of machine learning isn’t bad analytical tools or fear of statistics: it’s bad data resulting from poorly designed studies. Using scientific blueprints to organize people, process, tech, & data, Riffyn makes machine learning in science an everyday reality.

The voluminous discussion and conflicting language on scientific reproducibility over the past decade has obscured its meaning. But in fact, there is a very clear scientific meaning for reproducibility, one that has been thoroughly developed and routinely practiced around the world every day.

The 6th Accelerating Biopharmaceutical Development Conference (AccBio2019), hosted by AIChE from February 17-19, 2019 focused on the confluence of new therapy pathways, biologics process intensification, and using process development data to speed innovative therapies to market.

2018 was a record year for number of posts to the Discover Blog from the Riffyn team. We share the top blog posts in terms of views from this past year.

In 2018, we dramatically advanced our mission to bring computer-aided-design to scientific experimentation. 

If modern software engineering worked like science, programmers would not share open source code, they would take notes on their work and then publish long-form articles about their software. Months or years later, their colleagues would attempt to reproduce the software based on the article.